Patents by Inventor Scott F. Sneddon

Scott F. Sneddon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of TNF-? signaling
    Patent number: 9579325
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: February 28, 2017
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Frederic Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators Of TNF-Alpha Signaling
    Publication number: 20150126512
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 7, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Frederic Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-? signaling
    Patent number: 8921547
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: December 30, 2014
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Frederic Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-Alpha Signaling
    Publication number: 20130310388
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Application
    Filed: July 19, 2013
    Publication date: November 21, 2013
    Applicant: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, JR., Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-?signaling
    Patent number: 8518999
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: August 27, 2013
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-? signaling
    Patent number: 7034031
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: April 25, 2006
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-? signaling
    Patent number: 6969728
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: November 29, 2005
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-alfa signaling
    Publication number: 20040171617
    Abstract: The present invention provides compounds which are modulators of TNF-&agr; signaling and methods of use thereof for treating a patient having a TNF-&agr; mediated condition.
    Type: Application
    Filed: March 10, 2004
    Publication date: September 2, 2004
    Applicant: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Alpha acyloxyacetamides for kallikrein and urokinase inhibition
    Publication number: 20040044075
    Abstract: Disclosed herein is a compound represented by Structural Formula (I): 1
    Type: Application
    Filed: May 29, 2003
    Publication date: March 4, 2004
    Applicant: Genzyme Corporation
    Inventors: Mark M. Staveski, Scott F. Sneddon
  • Modulators of TNF-alpha signaling
    Publication number: 20020119988
    Abstract: The present invention provides compounds which are modulators of TNF-&agr; signaling and methods of use thereof for treating a patient having a TNF-&agr; mediated condition.
    Type: Application
    Filed: May 10, 2001
    Publication date: August 29, 2002
    Applicant: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill
  • Inha inhibitors and methods of use thereof
    Patent number: 6372752
    Abstract: The invention relates to compounds which inhibit the Mycobacterial enoyl-ACP reductase required for cell wall biosynthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of use of these compounds for treating a bacterial infection in a patient.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: April 16, 2002
    Assignee: Genzyme Corporation
    Inventors: Mark M. Staveski, Scott F. Sneddon, Christopher Yee, Andrew Janjigian